After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...